Takeda Pharmaceutical Company Limited (NYSE:TAK) on Monday said a Massachusetts jury awarded nearly $885 million in damages against the company in litigation tied to its constipation drug Amitiza (lubiprostone), with portions of the award subject to automatic trebling under U.S. antitrust law.
Takeda To Appeal AMITIZA Antitrust Verdict
Something went wrong.
Plaintiffs in the consolidated case alleged that a 2014 settlement agreement between Takeda, Sucampo Pharmaceuticals, and Par Pharmaceutical related to generic Amitiza delayed competition and violated antitrust laws.
The jury awarded $884.9 million in single damages. That included about $474.9 million awarded to a wholesaler class and roughly $346.8 million to individual retailers.
